

AUGUST 2021 Page 1 of 4

Test Name Test Code Effective Date

COVID-19 - Delta Variant TH68 N/A

Genetic variants of SARS-CoV-2 have been emerging and circulating around the world throughout the COVID-19 pandemic. Most notable variants are the B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) variants, which seem to spread more easily and quickly than other variants and may lead to more cases of COVID-19 in unvaccinated individuals.

An increase in the number of cases will put more strain on healthcare resources, lead to more hospitalizations, and potentially more deaths. These variants are considered 'Variants of Concern' by the CDC; variants for which there is evidence of an increase in transmissibility, and potential for more severe disease (e.g., increased hospitalizations or deaths). The Delta variant is estimated to account for up to 80% of new COVID-19 testing, as of July 19, 2021.

#### **Variant Testing**

While BioReference's COVID-19 testing platforms do not report the detection of any specified variant, our platforms are not affected by the various spike protein variants, including Delta. For example, if an individual is infected with the Delta variant, the individual will receive a positive COVID-19 result. The result will not specify any type of variant.

#### **Variant Detection and Treatment of Positive Cases**

The CDC has not issued new guidelines for individuals sick with Delta or other variants. At this time, individuals should follow guidelines for COVID-19, including:

- Stay home and isolate from other people
- Monitor symptoms and call a healthcare provider if symptoms worsen

### **Vaccination Breakthrough Cases**

BioReference does not collect vaccination status for individuals being tested for COVID-19. Therefore, we are unable to determine if we have had any vaccine breakthrough cases. As of July 6, 2021, the CDC reported 5,186 cases of breakthrough COVID-19 cases that led to severe disease among 157 million fully vaccinated people in the US. BioReference is cooperating with many State Departments of Health and providing positive COVID-19 PCR samples for epidemiologic purposes.

#### Coverage – Scarlet Health N/A August

We're pleased to share **Scarlet Health** ("Scarlet"), a division of BioReference Laboratories, Inc., is now available to members and reimbursed by UnitedHealthcare®. This distinction means that UnitedHealthcare members are now covered to receive a mobile alternative to traditional patient service centers.

Scarlet provides on-demand, mobile specimen collection from your patient's home or place of employment. Scarlet can be added to your regular laboratory order online via InsightDx, and appointments can be managed by your patient directly from their mobile phone.

Please contact your Account Executive or email hello@scarlethealth.com for more information.

#### Customer Satisfaction Survey N/A Immediately

Are you in need of wireless earbuds? By completing our **2021 Customer Satisfaction Survey**, you will be entered into a drawing for the chance to win a pair. Don't miss this opportunity to share your feedback about BioReference Laboratories and its subsidiaries. Visit bioreference.com/customersurvey to complete the survey.

The survey should only take you about 5 minutes. Your entry will remain separate from your survey responses to protect your anonymity. Employees of BioReference and their relatives are not eligible to participate.

GenPath is a business unit of BioReference Laboratories, Inc | © 2021 All rights reserved.

481 Edward H Ross Drive | Elmwood Park NJ 07407 | tel 800 229 5227 | fax 201 791 1941 | www.bioreference.com



**AUGUST 2021** Page 2 of 4

Test Name Test Code Effective Date
4Kscore® Test J148, J264, K135 Immediately

Healthcare providers nationwide can order the **4Kscore® Test** for patients.

Based on customer feedback, we have updated the 4Kscore Test requisition form. The information requirements to order the test have not changed. The requisition form has been modified to improve:

- The accuracy of 4Kscore Test orders submitted
- Specimen processing in the laboratory
- Turnaround time (TAT) for patient test results

#### Summary of Improvements:

- 1. Larger, separate boxes for Collected Date and Collected Time. BOTH of these fields on the requisition form must be completed.
- 2. Easier to read and understand all questions in the Prostate Cancer Risk Evaluation section ALL 5 questions must be completed.

Your Account Executive can provide you with additional details and information as needed. If you have any further questions, please call our 4Kscore Customer Service team at 833-4KSCORE (833-457-2673).

## Bath Salts Panel, Urine A885 July 12

Due to changes at our reference laboratory, test information for **Bath Salts Panel**, **Urine** has been updated. Please refer to the table below for changes.

	Previous Test Information	New Test Information	
Minimum Volume	0.4mL	1mL	
Stability	Ambient – n/a	Ambient – 7 days	
	Refrig – 7 days	Refrig – 30 days	
	Frozen – 30 days	Frozen – 30 days	
Profile Components	Methylone	alpha-PHP / alpha-PiHP	
	alpha-PVP	4-chloro alpha-PVP	
	Pentedrone	Eutylone	
	MDPV	Benzylone	
	Mephedrone	N-butyl Pentylone	
	Methoxetamine		

### Hereditary Spherocytosis B702 Immediately

Due to changes at our reference laboratory, test information for **Hereditary Spherocytosis** has been updated. Please refer to the table below for changes.

	Previous Test Information	New Test Information
Profile Components	Hemolytic Anemia Interpretation	Hemolytic Anemia Interpretation
	Reviewed By	Reviewed By
	Hemoglobin A2	Hb A
	Hemoglobin F	Hb F
	Hemoglobin A	Hb A2

- Continued on Next Page -

GenPath is a business unit of BioReference Laboratories, Inc | © 2021 All rights reserved.

481 Edward H Ross Drive | Elmwood Park NJ 07407 | tel 800 229 5227 | fax 201 791 1941 | www.bioreference.com



**OPKO** Health Companies

AUGUST 2021 Page 3 of 4

Test Name	Test Code	Effective Date
	Variant	Variant 1
1	Variant 2	Variant 2
	Variant 3	Variant 3
	Interpretation	HGBCE Interpretation
	Hemoglobin, Unstable, B	HPLC Hb Variant, B
	Osmotic Fragility, RBC	Hb Stability, B
	Osmotic Fragility, 0.50 g/dL NaCl	Osmotic Fragility, RBC
1	Osmotic Fragility, 0.60 g/dL NaCl	Osmotic Fragility, 0.50 g/dL NaCl
<u>                                     </u>	Osmotic Fragility, 0.65 g/dL NaCl	Osmotic Fragility, 0.60 g/dL NaCl
1	Osmotic Fragility, 0.75 g/dL NaCl	Osmotic Fragility, 0.65 g/dL NaCl
1	Osmotic Fragility Comment	Osmotic Fragility, 0.75 g/dL NaCl
1	Shipping Control Vial	Osmotic Fragility Comment
1	G-6-PD, QN, RBC	Shipping Control Vial
<u>                                     </u>	Pyruvate Kinase, RBC	Band 3 Fluorescence Staining, RBC
1	Glucose Phosphate Isomerase, B	G6PD Enzyme Activity, B
1	Hexokinase, B	PK Enzyme Activity, B
1	Morphology Review	Glucose Phosphate Isomerase, B
1		Hexokinase, B
<u>                                     </u>		Adenylate Kinase, B
1		Phosphofructokinase, B
<u>                                     </u>		Phosphoglycerate Kinase, B
1		Triosephosphate Isomerase, B
1		Glutathione, B
1		Pyrimidine 5' Nucleotidase, B
		Morphology Review
CPT Code(s)**	82657, 82955, 83020, 83021, 83068, 84087,	83020, 82657, 82955, 83020, 83021, 83068, 84087,
	84220, 85060, 85557, 88184	84220, 82657X5, 85060

#### Kappa Lt. Chains, Quant., Urine 24Hr.

3424

**Immediately** 

Due to changes at our reference laboratory, test information for **Kappa Lt. Chains, Quant., Urine 24Hr.** has been updated. Please refer to the table below for changes.

	Previous Test Information	New Test Information
Methodology	Nephelometry	Immunoturbidimetry
Reference Range	1.35-24.19 mg/L	< or = 32.90 mg/L
CPT Code(s)**	83883	83520

#### **REMINDER - COVID-19 for International Travel**

TL40

**Immediately** 

Please be reminded that the Novel Coronavirus COVID-19 for International Travel (codes TL40 & TL41) is available for ordering. This test is only intended for use on patients that will be travelling internationally and are required to show proof of real time RT-PCR assay test results. This test is available for \$100, self-payment option only.

NOTE: Patients need to confirm the specific test requirements with venue or airlines prior to testing. Requirements can vary by airline or destination, so please have patients confirm with destination to ensure they are tested at the right time. If patients receive the wrong type of test or are tested too early or late, patients may need to self-quarantine at their destination.

GenPath is a business unit of BioReference Laboratories, Inc | © 2021 All rights reserved.

481 Edward H Ross Drive | Elmwood Park NJ 07407 | tel 800 229 5227 | fax 201 791 1941 | www.bioreference.com

This fax transmission is only intended for current customers of BioReference Laboratories and its business units. If you have received this message in error or wish to be removed from our customer list, please call 1-888-681-5252, enter document number 700144 and follow the prompts, or send an unsubscribe fax to 1-844-249-7519 or email to clinicalmarketing@bioreference.com. If you would like to subscribe to receive these updates via email, please visit http://bioreferencelabs.bioreference.com/go-green.



OPKO Health Companies

AUGUST 2021 Page 4 of 4

Test Name Test Code Effective Date

REGIONAL UPDATE - INR A227 7-16-21

Reference range for **INR** has been updated when performed at the **Mineola, NY** laboratory location. Please refer to the table below for changes.

	Previous Test Information	New Test Information
Reference Range	0.91-1.10	0.94-1.15

<sup>\*</sup> TAT is based upon receipt of the specimen at the laboratory

GenPath is a business unit of BioReference Laboratories, Inc | © 2021 All rights reserved.
481 Edward H Ross Drive | Elmwood Park NJ 07407 | tel 800 229 5227 | fax 201 791 1941 | www.bioreference.com

<sup>\*\*</sup>CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payer being billed.